Exelixis
EXEL
#1725
Rank
โ‚ฌ9.17 B
Marketcap
32,12ย โ‚ฌ
Share price
-1.16%
Change (1 day)
50.55%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): โ‚ฌ0.55 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚ฌ2.08 Billion. In 2023 the company made an earning of โ‚ฌ0.24 Billion, an increase over its 2022 earnings that were of โ‚ฌ0.22 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) โ‚ฌ0.55 B121.59%
2023 โ‚ฌ0.24 B9.89%
2022 โ‚ฌ0.22 B-20.33%
2021 โ‚ฌ0.28 B124.82%
2020 โ‚ฌ0.12 B-67.14%
2019 โ‚ฌ0.38 B-11.94%
2018 โ‚ฌ0.43 B185.09%
2017 โ‚ฌ0.15 B-325.82%
2016 -โ‚ฌ67.75 Million-58.12%
2015 -โ‚ฌ0.17 Billion-37.61%
2014 -โ‚ฌ0.26 Billion9.75%
2013 -โ‚ฌ0.24 Billion65.96%
2012 -โ‚ฌ0.15 Billion-291.63%
2011 โ‚ฌ74.28 M-195.59%
2010 -โ‚ฌ77.71 Million-42.17%
2009 -โ‚ฌ0.14 Billion-18.98%
2008 -โ‚ฌ0.17 Billion-6.99%
2007 -โ‚ฌ0.18 Billion46.3%
2006 -โ‚ฌ0.13 Billion33.25%
2005 -โ‚ฌ91.48 Million-30.92%
2004 -โ‚ฌ0.14 Billion44.29%
2003 -โ‚ฌ91.77 Million12.86%
2002 -โ‚ฌ81.32 Million22.79%
2001 -โ‚ฌ66.23 Million60.14%
2000 -โ‚ฌ41.36 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
โ‚ฌ4.02 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ7.14 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ14.44 B 2,395.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ6.64 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ4.51 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ17.74 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ6.69 B 1,057.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ43.24 Million-107.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ28.02 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA